- Home
- BNT vs QGEN Comparison
BNT vs QGEN Comparison
Compare BNT & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNT | QGEN |
|---|---|---|
| Founded | 2020 | 1986 |
| Country | Bermuda | Netherlands |
| Employees | 4000 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 10.2B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | BNT | QGEN |
|---|---|---|
| Price | $45.48 | $38.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $50.26 |
| AVG Volume (30 Days) | 25.2K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | 0.62% | ★ 6.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | N/A | $5.71 |
| P/E Ratio | ★ $19.14 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.06 | $37.40 |
| 52 Week High | $74.16 | $57.82 |
Technical Indicators
Market Signals| Indicator | BNT | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 32.14 |
| Support Level | $44.62 | N/A |
| Resistance Level | $47.92 | $48.53 |
| Average True Range (ATR) | 1.09 | 0.84 |
| MACD | 0.11 | -0.13 |
| Stochastic Oscillator | 48.23 | 17.34 |
Price Performance
Historical ComparisonAbout BNT Brookfield Wealth Solutions Ltd.
Brookfield Wealth Solutions Ltd, formerly Brookfield Reinsurance Ltd operates a capital solutions business providing insurance and reinsurance services to individuals and institutions. Through its subsidiary, the company offers a broad range of insurance products and services, including life insurance and annuities, and personal and commercial property and casualty insurance. The Company's reporting segments are Annuities, P&C, Life Insurance and Corporate and Other. Majority revenue is generated from Annuities segment followed by P&C.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).